You are here

clinical trials

Will Real World Performance Replace RCTs As Healthcare's Most Important Standard?

Will Real World Performance Replace RCTs As Healthcare's Most Important Standard?

Forbes

clinical trials

real world evidence

Flag link:

Puma shares plummet as results from key trial delayed

Puma shares plummet as results from key trial delayed

Biopharma Dive

Puma Biotechnology

clinical trials

Flag link:

Novartis, Durect renegotiate $293M painkiller deal after phase 3 failure

Novartis, Durect renegotiate $293M painkiller deal after phase 3 failure

Fierce Biotech

post-operative pain

clinical trials

Flag link:

Innovation Provides Update on Ph II Trial of Brilacidin for Severe Oral Mucositis in Head and Neck Cancer

Innovation Provides Update on Ph II Trial of Brilacidin for Severe Oral Mucositis in Head and Neck Cancer

CP Wire

Innovation Pharmaceuticals

clinical trials

Flag link:

Autolus seeks $100M IPO to take next-gen CAR-Ts deep into the clinic

Autolus seeks $100M IPO to take next-gen CAR-Ts deep into the clinic

Fierce Biotech

clinical trials

Flag link:

Faron Pharmaceuticals Drug Traumakine Fails Ph III Trial

Faron Pharmaceuticals Drug Traumakine Fails Ph III Trial

CP Wire

Faron Pharmaceuticals

clinical trials

Flag link:

Regeneron halts high doses of phase 3 osteoarthritis drug fasinumab amid risk-benefit concerns

Regeneron halts high doses of phase 3 osteoarthritis drug fasinumab amid risk-benefit concerns

Fierce Biotech

clinical trials

Flag link:

Is InVivo's Neuro-Spinal Scaffold Back on Track After Halted Trial?

Is InVivo's Neuro-Spinal Scaffold Back on Track After Halted Trial?

Medical Devices and Diagnostics Industry

Invivo Therapeutics

neuro-spinal scaffold

clinical trials

spinal implants

Flag link:

Esperion tumbles as patient deaths weigh on cholesterol drug

Esperion tumbles as patient deaths weigh on cholesterol drug

Biopharma Dive

Esperion Therapeutics

clinical trials

Flag link:

Karyopharm to pursue FDA approval for multiple myeloma drug based on new study results

Karyopharm to pursue FDA approval for multiple myeloma drug based on new study results

Stat

Karyopharm Therapeutics

Multiple Myeloma

clinical trials

Flag link:

NanOlogy Completes Dose Escalation Portion of Phase 2 Trial of Unique NanoPac for Prostate Cancer

NanOlogy Completes Dose Escalation Portion of Phase 2 Trial of Unique NanoPac for Prostate Cancer

CP Wire

clinical trials

prostate cancer

Flag link:

GI toxicity hits midstage Sanofi GLP-1 drug as patients drop out

GI toxicity hits midstage Sanofi GLP-1 drug as patients drop out

Fierce Biotech

clinical trials

Flag link:

Alzheon steps back from an IPO, further than ever from a PhIII Alzheimer’s study

Alzheon steps back from an IPO, further than ever from a PhIII Alzheimer’s study

Endpoints

Alzheimer's disease

clinical trials

Flag link:

Eyeing blockbuster migraine market, Allergan unloads second set of positive PhIII results for ubrogepant

Eyeing blockbuster migraine market, Allergan unloads second set of positive PhIII results for ubrogepant

Endpoints

clinical trials

Flag link:

First Patient Dosed in Avexis' Phase 3 Trial of AVXS-101 in Pre-Symptomatic Spinal Muscular Atrophy

First Patient Dosed in Avexis' Phase 3 Trial of AVXS-101 in Pre-Symptomatic Spinal Muscular Atrophy

CP Wire

clinical trials

spinal muscular atrophy

Flag link:

AbbVie's Upadacitinib Meets Primary and Key Efficacy Endpoints in Phase 2b/3 Rheumatoid Arthritis Study

AbbVie's Upadacitinib Meets Primary and Key Efficacy Endpoints in Phase 2b/3 Rheumatoid Arthritis Study

CP Wire

rheumatoid arthritis

clinical trials

Flag link:

FDA Pumps the Brakes on Epizyme’s Top Cancer Drug Tazemetostat

FDA Pumps the Brakes on Epizyme’s Top Cancer Drug Tazemetostat

Xconomy

clinical trials

Flag link:

Merck’s Relebactam Met Primary Endpoints in Phase 3 Study

Merck’s Relebactam Met Primary Endpoints in Phase 3 Study

Market Realist

beta-lactamase inhibitors

clinical trials

Flag link:

Prothena’s lead drug NEOD001 just imploded in 2 late-stage studies — and there’s nothing left to salvage

Prothena’s lead drug NEOD001 just imploded in 2 late-stage studies — and there’s nothing left to salvage

Endpoints

clinical trials

Flag link:

ImmuPharma dives on late-stage lupus failure

ImmuPharma dives on late-stage lupus failure

Biopharma Dive

clinical trials

Flag link:

Pages